IN2014MN01901A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01901A
IN2014MN01901A IN1901MUN2014A IN2014MN01901A IN 2014MN01901 A IN2014MN01901 A IN 2014MN01901A IN 1901MUN2014 A IN1901MUN2014 A IN 1901MUN2014A IN 2014MN01901 A IN2014MN01901 A IN 2014MN01901A
Authority
IN
India
Prior art keywords
acidic
sensitive
disclosed
dosage form
active agent
Prior art date
Application number
Other languages
English (en)
Inventor
Akwete L Adjei
Sibao Chen
Robert Joe Kupper
Vincent Mancinelli
Original Assignee
Rhodes Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhodes Pharmaceuticals Lp filed Critical Rhodes Pharmaceuticals Lp
Publication of IN2014MN01901A publication Critical patent/IN2014MN01901A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN1901MUN2014 2012-03-02 2013-03-01 IN2014MN01901A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606156P 2012-03-02 2012-03-02
US201261724141P 2012-11-08 2012-11-08
PCT/IB2013/000444 WO2013128276A2 (fr) 2012-03-02 2013-03-01 Formulations à libération immédiate inviolables

Publications (1)

Publication Number Publication Date
IN2014MN01901A true IN2014MN01901A (fr) 2015-07-10

Family

ID=48044945

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1901MUN2014 IN2014MN01901A (fr) 2012-03-02 2013-03-01

Country Status (21)

Country Link
US (3) US11173155B2 (fr)
EP (2) EP2819653B1 (fr)
JP (2) JP6199321B2 (fr)
CN (2) CN109820830A (fr)
AR (1) AR090218A1 (fr)
AU (2) AU2013203493B2 (fr)
CA (1) CA2852042C (fr)
CL (1) CL2014002283A1 (fr)
EA (1) EA028224B1 (fr)
ES (2) ES2619574T3 (fr)
IL (1) IL234256B (fr)
IN (1) IN2014MN01901A (fr)
MX (1) MX354677B (fr)
NZ (1) NZ629468A (fr)
PE (1) PE20142320A1 (fr)
PH (1) PH12014501910A1 (fr)
SG (1) SG11201405011PA (fr)
TW (2) TWI614037B (fr)
UY (1) UY34651A (fr)
WO (1) WO2013128276A2 (fr)
ZA (1) ZA201405960B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004084868A1 (fr) 2003-03-26 2004-10-07 Egalet A/S Systeme de liberation regulee de morphine
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
EP3090743A1 (fr) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Compositions pharmaceutiques
CA2713128C (fr) 2008-01-25 2016-04-05 Gruenenthal Gmbh Forme posologique pharmaceutique
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
CA2767576C (fr) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Compositions pharmaceutiques refermant un antiemetique et un analgesiqueopioide
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (fr) 2012-04-18 2018-08-22 Grünenthal GmbH Forme pharmaceutique inviolable et résistante au basculement de dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP3003279A1 (fr) 2013-05-29 2016-04-13 Grünenthal GmbH Forme pharmaceutique inviolable contenant une ou plusieurs particules
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EA032013B1 (ru) * 2013-10-31 2019-03-29 Сайма Лэбс Инк. Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
EP3073994A1 (fr) 2013-11-26 2016-10-05 Grünenthal GmbH Préparation de composition pharmaceutique en poudre par cryo-broyage
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015120201A1 (fr) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Formulations de médicament résistantes aux abus avec protection intégrée contre le surdosage
WO2015145461A1 (fr) * 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Forme galénique solide de matrice biphasique à libération immédiate et dissuasive d'abus
WO2015173195A1 (fr) 2014-05-12 2015-11-19 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016094358A1 (fr) * 2014-12-08 2016-06-16 Cima Labs Inc. Formes galéniques en granulés à libération immédiate, à effet anti-abus
WO2016170097A1 (fr) 2015-04-24 2016-10-27 Grünenthal GmbH Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant.
EP3285746A1 (fr) * 2015-04-24 2018-02-28 Grünenthal GmbH Combinaison de dose fixe inviolable permettant la libération rapide de deux médicaments à partir de particules et d'une poudre
EP3285744A1 (fr) * 2015-04-24 2018-02-28 Grünenthal GmbH Combinaison à dose fixe inaltérable présentant une libération rapide de deux médicaments de particules et d'une matrice
AU2016251851A1 (en) * 2015-04-24 2017-11-09 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
WO2016170096A1 (fr) 2015-04-24 2016-10-27 Grünenthal GmbH Combinaison inviolable de doses fixes permettant la libération rapide de deux médicaments à partir de particules différentes
WO2016200960A1 (fr) * 2015-06-09 2016-12-15 KVK-Tech, Inc. Compositions pharmaceutiques dissuasives d'abus
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
WO2018071381A1 (fr) * 2016-10-10 2018-04-19 Rhodes Pharmaceuticals L.P. Compositions pharmaceutiques à base de résinate et leurs procédés de fabrication et d'utilisation
ES2906979T3 (es) * 2016-12-21 2022-04-21 Tioga Pharmaceuticals Inc Formulaciones farmacéuticas sólidas de asimadolina
AU2018347991A1 (en) 2017-10-09 2020-05-07 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2022233885A2 (fr) * 2021-05-03 2022-11-10 Cambridge Glycoscience Ltd Compositions de saccharides solubles et insolubles et procédés associés
AU2023218629A1 (en) * 2022-02-09 2024-08-01 Drotastar Llc A pharmaceutical combination of antispasmodic and anxiolytic agent

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6740341B1 (en) 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003013476A1 (fr) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions et procedes servant a empecher la surconsommation d'opioides
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040091544A1 (en) 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
WO2004067039A1 (fr) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Compositions multiparticulaires de milnacipran destinees a etre administrees par voie orale
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CA2540308C (fr) * 2003-09-26 2013-08-06 Alza Corporation Enrobage de medicaments a charge medicamenteuse elevee et procedes de fabrication
DE602004030931D1 (fr) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2006124890A1 (fr) * 2005-05-13 2006-11-23 Alpharma, Inc. Formulations de sulfate de morphine
RU2496480C2 (ru) 2005-12-28 2013-10-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат с контролируемым высвобождением
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
WO2007120135A1 (fr) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Composition à libération immédiate de lercanidipine
JP5276991B2 (ja) * 2006-04-27 2013-08-28 武田薬品工業株式会社 固形製剤
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2904225B1 (fr) * 2006-07-28 2010-08-13 Bouchara Recordati Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
WO2010038688A1 (fr) * 2008-09-30 2010-04-08 アステラス製薬株式会社 Composition pharmaceutique particulaire pour une administration orale d’atorvastatine
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
WO2010066034A1 (fr) * 2008-12-12 2010-06-17 Paladin Labs Inc. Préparation de méthadone
ES2509497T3 (es) * 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9254329B2 (en) * 2009-10-28 2016-02-09 Basf Se Stable protective coatings for pharmaceutical dosage forms
BR112013034051A2 (pt) 2011-06-29 2019-09-24 Allergan Inc formulações de macrogol 15 hidroxiestearato
JP6110384B2 (ja) * 2011-09-16 2017-04-05 パーデュー ファーマ エルピー 不正改変抵抗性医薬製剤

Also Published As

Publication number Publication date
AU2013203493B2 (en) 2016-02-04
ES2619574T3 (es) 2017-06-26
CN109820830A (zh) 2019-05-31
US20220031693A1 (en) 2022-02-03
EA028224B1 (ru) 2017-10-31
TW201350142A (zh) 2013-12-16
US11173155B2 (en) 2021-11-16
NZ629468A (en) 2017-08-25
PH12014501910B1 (en) 2014-11-24
US20240423974A1 (en) 2024-12-26
EP3170492A1 (fr) 2017-05-24
EP2819653A2 (fr) 2015-01-07
MX354677B (es) 2018-03-15
CN104144681A (zh) 2014-11-12
ZA201405960B (en) 2016-03-30
US20150030677A1 (en) 2015-01-29
JP6509287B2 (ja) 2019-05-08
US12128042B2 (en) 2024-10-29
EA201400972A1 (ru) 2015-02-27
TW201722406A (zh) 2017-07-01
SG11201405011PA (en) 2014-09-26
MX2014010534A (es) 2015-05-11
AU2013203493A1 (en) 2013-09-19
TWI614037B (zh) 2018-02-11
CA2852042A1 (fr) 2013-09-06
PE20142320A1 (es) 2015-01-16
AU2016202846B2 (en) 2017-06-01
CL2014002283A1 (es) 2015-04-17
UY34651A (es) 2013-09-30
PH12014501910A1 (en) 2014-11-24
JP2018012711A (ja) 2018-01-25
ES2821773T3 (es) 2021-04-27
CA2852042C (fr) 2018-05-01
EP2819653B1 (fr) 2017-01-11
JP2015511953A (ja) 2015-04-23
WO2013128276A2 (fr) 2013-09-06
IL234256B (en) 2020-08-31
AU2016202846A1 (en) 2016-05-26
EP3170492B1 (fr) 2020-07-08
AR090218A1 (es) 2014-10-29
JP6199321B2 (ja) 2017-09-20
WO2013128276A3 (fr) 2013-12-27

Similar Documents

Publication Publication Date Title
IN2014MN01901A (fr)
IL222161A (en) Gamma-hydroxybutyrate immediate release and dosage forms
IL272501A (en) Oral administration forms of bendamustine and their medical use
TN2015000380A1 (en) Heterocyclic compounds and their uses
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
IL235831A0 (en) A new dosage form and formulation of aveditrol
PH12015501096A1 (en) Composition for immediate and extended release
IL231482A (en) Oral dosage forms of immediate release vehicles are immune to abuse
PL3056187T3 (pl) Jednodawkowy preparat farmaceutyczny hormonów tarczycowych t3 i/lub t4
TR201008226A2 (tr) Kapsül içeren bir inhalasyon cihazı.
CO7200262A2 (es) Nueva dosificación y formulación
HUE050945T2 (hu) Gyógyszerforma hatóanyagok nyújtott felszabadítására
IL223311A0 (en) Oral dosage forms of bendamustine
IL236466B (en) Pharmaceutical composition for the release of active components
EP2615908A4 (fr) Système pour l'administration orale d'un agent à un animal
IL239670B (en) Monolithic administration form for delayed release of a combination of active substances
IL238406A0 (en) Mixed inhibitors of aminopeptidase n and nephrilysin
SI2988782T1 (sl) Odmerne oblike za peroralno dajanje učinkovin
TR201005419A2 (tr) Valsartan içeren farmasötik bileşim.
UY33803A (es) Formas de dosificación de liberación modificada novedosas de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa
GB201019978D0 (en) Cotton face mask
GB201209165D0 (en) Compounds for treatment of destructive periodontal disease and pharmacological formulations thereof
AU2012901130A0 (en) A composition and method for enhancing the permeability of a tissue of a subject to an active agent